QT Vascular (IPO)

QT Vascular: QT Vascular produces devices to treat diseased arteries in the heart and elsewhere, aims to develop new products and enhance its existing ones. The company, which operates out of California and Singapore, registered revenue of US$1.5m for FYSep12, and doubled to US$3m in FY13. Current flagship product is a balloon catheter known as the "Chocolate" PTA balloon device, which is implanted to treat peripheral artery disease, or blocked arteries in the leg. It is the first Singapore-designed device to win approval from the US FDA. The company counts multi-national pharmaceutical company Johnson & Johnson, the Economic Development Board's Biomedical Sciences Investment Fund, and homegrown Juniper Capital among its major shareholders. QT Vascular is working with UOB Kay Hian and Prime Partners for the IPO. Preliminary prospectus can be found at http://www.sgx.com/wps/wcm/connect/ea5af5a7-ee40-4cae-b85d-cbdc05071633/QT+Vascular+Ltd.+Preliminary+Offer+Document.pdf?MOD=AJPERES&CONVERT_TO=url&CACHEID=ea5af5a7-ee40-4cae-b85d-cbdc05071633